Molina Healthcare Revenue Jumps in Q2

Molina Healthcare (NYSE:MOH) reported mixed Q2 2025 results, with GAAP revenue reaching $11.43 billion, exceeding expectations by 4.3% driven by premium growth and acquisitions. However, adjusted earnings per share of $5.48 missed estimates, primarily due to significant margin pressure from higher medical costs, pushing the Medical Care Ratio to 90.4%. Consequently, the company cut its full-year 2025 earnings guidance, signaling persistent profitability challenges despite robust top-line expansion and membership gains, while also noting negative operating cash flow for the first half of the year and a decline in parent company cash.

Analysis

Molina Healthcare's Q2 2025 results illustrate a significant divergence between top-line growth and bottom-line profitability. GAAP revenue grew a robust 15.7% year-over-year to $11.43 billion, surpassing estimates by 4.3%, fueled by strategic acquisitions like ConnectiCare and a near doubling of premium revenue in the Marketplace segment. This growth strategy also led to a net increase of 167,000 members year-over-year. However, this expansion was overshadowed by a severe compression in margins, evidenced by the consolidated Medical Care Ratio (MCR) rising 180 basis points to 90.4%. This increase, driven by higher utilization costs across all segments and integration challenges, caused adjusted EPS to miss expectations at $5.48 and decline 6.5% from the prior year. The negative financial implications are further underscored by a cut in full-year 2025 adjusted EPS guidance to no less than $19.00, negative operating cash flow of $112 million for the first half of the year, and a sharp drop in parent company cash reserves to approximately $100 million from $445 million at year-end 2024. While the company's ability to secure contracts and grow membership is intact, its inability to manage rising medical costs has materially weakened its earnings outlook and financial position.

Key Decisions for Investors

• Investors should weigh Molina's demonstrated revenue growth capabilities against the significant, ongoing margin pressure and the lowered full-year earnings guidance, which signals that management expects cost challenges to persist.
• Closely monitor the Medical Care Ratio (MCR) evolution in the upcoming quarters, as improvements in cost management, particularly within the Marketplace segment and the integration of ConnectiCare, are now critical to restoring profitability.
• Scrutinize the company's balance sheet and cash flow statements for stabilization, given the negative operating cash flow in H1 2025 and the substantial reduction in parent-level cash and investments.
• Track Medicaid membership trends as a key performance indicator, as ongoing eligibility redeterminations present a headwind that could offset growth achieved in other business lines.